Mylan Generic Epoprostenol Sodium Receives Approval in US
Viatris, the biopharma formed by the merger of generic giants Mylan and Pfizer’s Upjohn, is leaning into its branded products. Its growth strategy includes doubling down on brand management along with an anticipated $500 million-plus in new product launch sales this year, said president Rajiv Malik during its Q1 earnings on Monday.